Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Citations Over TimeTop 10% of 2005 papers

Abstract

Evidence from uncontrolled studies indicates that the treatment with imatinib brings about clinically significant shrinkage of tumour mass in about half of patients with unresectable and/or metastatic, KIT-positive GIST. Results of modelling based on data from uncontrolled studies suggest that imatinib treatment improves survival in patients with unresectable and/or metastatic GIST. The economic evaluation modelling suggests that the cost per QALY gained ranges from 51,515 to 98,889 UK pounds after 2 years, from 27,331 to 44,236 UK pounds after 5 years, and from 21,404 to 33,976 UK pounds after 10 years. Further research is needed into quality of life within trials involving patients with advanced malignancy, and long-term follow-up of adverse events is needed. Subgroup analysis of which, if any, patient types have a better or worse response to imatinib is also required. Analysis of individual patient data may be a good way of exploring these issues. There are many uncertainties surrounding imatinib prescription, such as the length of time patients should be on imatinib, the dose, drug resistance and the optimum time-point in the disease course at which to give the drug. Secondary research such as an update of this systematic review and a reassessment of the model is highly recommended when ongoing trials reach completion.

Related Papers

• → Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients(2003)143 cited
• → Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors(2012)29 cited
• → Gastrointestinal Stromal Tumor (GIST) - Single Center Experience of prolonged treatment with Imatinib(2005)13 cited
• → Imatinib Dose Interruption in GIST: High Progression Risk for 3-YearResponders(2007)
• Research Progress of Imatinib Preoperative Chemotherapy in Treatment of Advanced Gastrointestinal Stromal Tumor(2014)